Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 2,301–2,400 of 4,108
Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?
Gavrilov, Z., & Lojk, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146924 · Cited by 7
“In such cases, pharmaceutical treatment approaches are needed; however, so far, only drugs addressing osteoporosis are being used in routine clinical practice [34,36,37].”
Hu, F., Jing, F., Zhao, D. B., et al. (2025) · Clinical Radiology · doi:10.1016/j.crad.2025.107063 · Cited by 5
Edwards, F. D., Grover, M. L., Cook, C. B., & Chang, Y.-H. H. (2014) · Women s Health Issues · doi:10.1016/j.whi.2014.06.006 · Cited by 6
Low bone mass secondary to antipsychotic medications
Sadat-Ali, M., Al-Omran, A. S., Abumadini, M. S., Alfaraidy, M., & Shihada, W. (2016) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/1658-631x.188246 · Cited by 6
Graff, J. S., Shih, C., Barker, T., Dieguez, G., Larson, C., Sherman, H., & Dubois, R. W. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.16009 · Cited by 5
Safaei-Nodehi, R., Esmaili, J., Sharifian, R., et al. (2017) · PubMed · doi:10.22088/cjim.8.2.91 · Cited by 5
Burns, R. B., Smith, C. C., Shmerling, R. H., & Tess, A. V. (2018) · Annals of Internal Medicine · doi:10.7326/m18-2548 · Cited by 5
A pharmacist-run anabolic osteoporosis clinic: An abaloparatide descriptive report
McGreevy, J. L., Kane, M. P., Busch, R. S., Bakst, G., & ElDeiry, S. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.03.017 · Cited by 5
Pal, R., Aggarwal, A., Sachdeva, N. K., Ram, S., Garg, A., Bhansali, A. K., & Bhadada, S. K. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-020-00855-9 · Cited by 6
Seasonal Variation and Global Public Interest in the Internet Searches for Osteoporosis
Wang, C., Shu, X., Tao, J., Zhang, Y., Yuan, Y., & Wu, C. (2021) · BioMed Research International · doi:10.1155/2021/6663559 · Cited by 6
“The National Osteoporosis Foundation (NOF) strongly recommends lifelong physical activity at all ages, for both osteoporosis prevention and overall health [42].”
BackgroundNayak, S., & Greenspan, S. L. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06010-5 · Cited by 4
Stathopoulos, K. D., Chronopoulos, E., Galanos, A., Kaskani, E., Drakopoulou, T., Ibro, E., Tsekoura, M., & Kosmidis, C. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-01033-1 · Cited by 5
“These are in accordance with both the ISCD [15] and the NOF [16] guidelines that both seem to favour spine imaging (VFA or radiography) in patients with osteopenia or osteoporosis either of older age (women older than 70 years and men older than 80 years), while for younger patients, additional risk factors are needed.”
ResultA clinician's guide to the management of geriatric musculoskeletal disease: Part 1 - Osteoporosis
Feehan, J., Tripodi, N., Fleischmann, M., Zanker, J., & Duque, G. (2021) · International journal of osteopathic medicine · doi:10.1016/j.ijosm.2021.12.003 · Cited by 5
Deborah, A., Sherpa, M. L., Singh, A., et al. (2021) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_73_21 · Cited by 5
“5 SD).[2] The drawbacks of this have been that the definition reflects the physical damage (i.”
Backgroundda Silva, A. R. B., Martinez, L. C., Pinheiro, M. A. A., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01092-y · Cited by 5
“Osteoporosis is considered a relevant public health problem with significant social and financial impacts [1].”
BackgroundXing, Y., Liu, J., Liu, H., & Ma, H. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s384694 · Cited by 5
“As a result, BTMs have been recognized as a promising tool for assessing bone quality and metabolism by the National Osteoporosis Foundation.(25) Specifically, PINP is secreted by osteoblasts during the formation of bone collagen.”
MethodMiedany, Y. M. E., Gadallah, N. A., Sarhan, E., et al. (2022) · Kidney Diseases · doi:10.1159/000526492 · Cited by 5
Patel, K., Salama, S., & Cottreau, J. M. (2022) · Orthopaedic Nursing · doi:10.1097/nor.0000000000000899 · Cited by 5
The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
Inojosa, A. C., Mendes, L., Bandeira, L., & Bandeira, F. A. F. (2022) · Journal of Bone Metabolism · doi:10.11005/jbm.2022.29.4.217 · Cited by 5
“[5-7] Among the BPs, alendronate (ALE) and zoledronate (ZOL) can be absorbed into the bone matrix for a long time, thus having a residual and even permanent effect.[1,2] Although there have been reports of vertebral fractures linked with DMAB withdrawal in recent years,[8-18] the mechanism and risk factors for this ph…”
BackgroundInfluentialLiver enzyme inducing anticonvulsant drug use is associated with prevalent vertebral fracture
Schousboe, J. T., Binkley, N., & Leslie, W. D. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06820-9 · Cited by 5
“The program maintains a database of all dual-energy x-ray absorptiometry (DXA) results, with a completeness and accuracy in excess of 99%, that can be linked with other provincial population-based computerized health databases (including pharmacy claims) through an anonymous personal identifier [12].”
BackgroundInfluentialHammel, J., Birnbacher, L., Campbell, G. M., Coulon, P., Ushakov, L., Pfeiffer, F., Makowski, M. R., Kirschke, J. S., & Pfeiffer, D. (2023) · European Radiology Experimental · doi:10.1186/s41747-023-00356-7 · Cited by 7
“Discussion DEXA is a 2D spectral technique for the assessment of aBMD and is the reference standard for diagnosing osteoporosis [29].”
BackgroundPerformance of FRAX in older adults with frailty: the Framingham Heart Study
Chattaris, T., Yang, L., Johansson, H., Sahni, S., Samelson, E. J., Kiel, D. P., & Berry, S. D. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06950-0 · Cited by 6
“Few older women received osteoporosis medications at that time [47], and so, we expect little change.”
Aurégan, J.-C., Bosser, C., Bachy, M., Bensidhoum, M., & Hoc, T. (2023) · Bioengineering · doi:10.3390/bioengineering10121338 · Cited by 5
“In particular, mineral content is a major determinant of its strength, which can be measured in vivo using dual-energy X-ray absorptiometry (DEXA) in certain areas of the skeleton to identify osteoporotic patients and determine the risk of bone fracture [6,7].”
BackgroundVincent, J. I., MacDermid, J. C., Bassim, C. W., & Santaguida, P. L. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01350-7 · Cited by 6
“However, clinical practice guidelines [45, 46] recommend a bone mineral density test in the following cases: in all women over 65 and men over 70 years of age; individuals who break a bone after age 50; a woman of menopausal age with risk factors; and postmenopausal woman under age 65 with risk…”
BackgroundEvaluation of Bone Mineral Density in Lung Transplant Recipients by Chest Computed Tomography
Mori, R., Handa, T., Ohsumi, A., Ikezoe, K., Tanizawa, K., Uozumi, R., Tanabe, N., Oguma, T., Sakamoto, R., Hamaji, M., et al. (2023) · Respiration · doi:10.1159/000535269 · Cited by 6
“Osteoporosis was de fi ned as a mean BMD below − 2.5 SD of the YAM, and osteopenia was de fi ned as a mean BMD from − 2.5 SD to − 1 SD of the YAM [15].”
BackgroundInfluentialThree cases highlighting possible discrepancies in the interpretation of transgender DXA scores
Torre, S. C. D. L., Godar, C. M., Shakir, M. K. M., & Hoang, T. D. (2024) · Clinical Case Reports · doi:10.1002/ccr3.8451 · Cited by 5
Köroğlu, E. Y., Tam, A. A., Fakı, S., et al. (2024) · HORMONES · doi:10.1007/s42000-024-00530-5 · Cited by 5
“The World Health Organization’s criteria were used when interpreting DEXA-BMD results [13].”
Xiao, X., & Wu, Q. F. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07105-5 · Cited by 5
“We designated “high risk” as the predicted MOF risk ≥ 20% and “low risk” as the predicted MOF risk 20%, based on the National Osteoporosis Foundation’s recommended fixed intervention cutoff [41].”
BackgroundCazzolla, A. P., Brescia, V., Lovero, R., Fontana, A., Giustino, A., Dioguardi, M., Comite, M. D., Serio, F. D., Ciavarella, D., & Crincoli, V. (2024) · Dentistry Journal · doi:10.3390/dj12070209 · Cited by 8
Dias, B. S. S., Querrer, R., Figueiredo, P. T. D. S., Leite, A. F., de Melo, N. S., Costa, L. R., Caetano, M. F., & Farias, M. C. Q. (2024) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2024.107031 · Cited by 10
Osteoporosis in men—East and West: Can the twain meet? A perspective from Asia
Sng, G. G. R., Reginster, J., Alokail, M. S., & Chandran, M. (2024) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2024.11.001 · Cited by 12
“Others have suggested universal screening with DXA for all men above 65 years [61] or 70 years of age [62,63].”
Lanzolla, G., Sabini, E., Beigel, K., Khan, M. P., Liu, X. S., Wang, D., Laslow, B., Taylor, D. M., Bellido, T., Giaccia, A. J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416004121 · Cited by 5
“Although several options exist for treating established bone mass loss, few preventive options are available for at - risk patients, such as those with osteopenia—a condition characterized by bone mineral density (BMD) lower than normal but not severe enough to be classified as osteoporosis ( 16 ).”
Clinical Implications of Serotonin Regulation of Bone Mass
Haney, E. M., Calarge, C. A., & Bliziotes, M. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-415784-2.00016-6 · Cited by 6
Osteoporosis Prevention: Narrowing the Gap Between Knowledge and Application
Sabin, N. J., & Sarter, B. (2014) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2014.07.019 · Cited by 5
Yoo, J. W., Kim, S. J., Lee, J. Y., Kim, S., Nakagawa, S., Bertelson, H., & Lam, J. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s62780 · Cited by 5
Gasier, H. G., Hughes, L. M., Young, C. R., & Richardson, A. M. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2753-y · Cited by 5
Public health in pharmacy: Improving vitamin D status in the U.S. population
Broussard, D. L. (2013) · Journal of the American Pharmacists Association · doi:10.1331/japha.2013.12106 · Cited by 5
Zhao, Y., Johnston, S. S., Smith, D. M., McMorrow, D., Krege, J. H., & Krohn, K. (2013) · Bone · doi:10.1016/j.bone.2013.12.016 · Cited by 6
Evaluation and Medical Management of Fragility Fractures of the Upper Extremity
Gutowski, C. J., & Ilyas, A. M. (2014) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2013.12.005 · Cited by 5
Cano, A., Baró, F., Fernández, C., Inaraja, V., & García-Domínguez, C. A. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.02.014 · Cited by 7
Bisphosphonates beyond five years
Paskins, Z., & Warburton, L. (2016) · BMJ · doi:10.1136/bmj.i264 · Cited by 5
Casciaro, S., Pisani, P., Conversano, F., Renna, M. D., Soloperto, G., Casciaro, E., Quarta, E., Grimaldi, A., & Muratore, M. (2015) · IET Science Measurement & Technology · doi:10.1049/iet-smt.2015.0056 · Cited by 6
Osteoporosis: Prevention and Treatment
Zaheer, S., & LeBoff, M. S. (2016) · Cited by 8
Self-citationPrimary Care Endocrinology in the Adult Woman
Thomas, C. C., & Zeytinoglu, M. (2016) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2016.01.005 · Cited by 4
Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of Falls
Choksi, P. U., & Williams, M. (2016) · Journal of Bone Reports & Recommendations · doi:10.4172/2469-6684.100023 · Cited by 5
Changing Patterns in Oral Bisphosphonate Initiation in Women between 2004 and 2012
Lee, D. R., Ettinger, B. B., Chandra, M., Hui, R. L., & Lo, J. C.-M. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14723 · Cited by 5
Essentials of Menopause Management
Sayegh, R. A., & Pal, L. (2017) · Springer eBooks · doi:10.1007/978-3-319-42451-4 · Cited by 5
Hemmeler, C., Morell, S., Amsler, F., & Groß, T. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0334-3 · Cited by 4
Correa‐Rodríguez, M., Schmidt‐RioValle, J., & Rueda‐Medina, B. (2017) · Annals of Human Genetics · doi:10.1111/ahg.12235 · Cited by 6
Theodorakidou, M., Nikola, O. A., & Lambrou, G. Ι. (2018) · Journal of Research and Practice on the Musculoskeletal System · doi:10.22540/jrpms-02-022 · Cited by 8
Horai, T., Hishimoto, A., Otsuka, I., So, T., Mouri, K., Shimmyo, N., Boku, S., Okishio, N., & Sora, I. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s153360 · Cited by 8
Appropriateness of bone density measurement in Switzerland: a cross-sectional study
Zechmann, S., Scherz, N., Reich, O., Brüngger, B., Senn, O., Rosemann, T. J., & Neuner‐Jehle, S. (2018) · BMC Public Health · doi:10.1186/s12889-018-5305-0 · Cited by 5
Yoga Practice for The Elderly: Good Choice to Avoid Falls
Boros, S., Csala, B., & Szilágyi, E. (2018) · Journal of Exercise Sports & Orthopedics · doi:10.15226/2374-6904/5/1/00166 · Cited by 5
Clinical performance of seven prescreening tools for osteoporosis in Iranian postmenopausal women
Keshtkar, A., Tabatabaie, O., Matin, N., Mohammadi, Z., Ebrahimi, M., Khashayar, P., & Asadi, M. (2015) · Rheumatology International · doi:10.1007/s00296-015-3286-1 · Cited by 5
Relationship between the FRAX index and physical and cognitive functioning in older people
Silva, Y. G., Manteca, L. A., Gallego, H. D. L. R., Muñoz, M. Á., Carbajo, M. R., Casado, T. M., Ausín, L., Otero, J. A., & Pérez-Castrillón, J.-L. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1505052 · Cited by 7
The prevalence of overtreatment of osteoporosis: results from the PAADRN trial
Hall, S. F., Wright, N. C., Wolinsky, F. D., Lou, Y., Edmonds, S. W., Roblin, D. W., Jones, M., Saag, K. G., & Cram, P. M. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0517-6 · Cited by 6
Heyman, N., Etzion, I., & Natan, M. B. (2018) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2018.11.084 · Cited by 5
Mabrouk, M. M., Hammad, S. F., Abdelaziz, M. A., et al. (2019) · Analytical Chemistry Letters · doi:10.1080/22297928.2019.1605928 · Cited by 5
Secondary causes of Osteoporosis
Chionh, S. B. (2019) · The Singapore Family Physician · doi:10.33591/sfp.44.3.u2 · Cited by 5
Implementing a fracture follow-up liaison service: perspective of key stakeholders
Luc, M., Corriveau, H., Boire, G., Filiatrault, J., Beaulieu, M., Dagenais, P., & Gaboury, I. (2019) · Rheumatology International · doi:10.1007/s00296-019-04413-6 · Cited by 9
Yang, Y., Liu, G., Zhang, Y., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00497 · Cited by 5
Razaly, N. I., Mohammad, A., Shamsir, M., Nadia, M. E., & Mohd Dzulkhairi, M. R. (2020) · IIUM Medical Journal Malaysia · doi:10.31436/imjm.v18i1.231 · Cited by 7
“effects such as renal problem, eye inflammation, osteonecrosis of the jaw bone, malignancy and increased risk of deep vein thrombosis.(9,10) This has led to the discovery of alternative anti-osteoporotic agents based on natural products with minimal side effects.”
BackgroundRoxas, M. C. A., Jimeno, C., Palileo‐Villanueva, L. M., Macalalad-Josue, A. A., Sandoval, M. A., & Fernandez, J. A. (2020) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.035.01.15 · Cited by 5
Cirrincione, L. R., & Narla, R. R. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa213 · Cited by 8
Bone healing: Advances in biology and technology
Mullis, B., Gudeman, A., Borrelli, J., Crist, B. D., Lee, M., & Evans, A. R. (2021) · OTA International The Open Access Journal of Orthopaedic Trauma · doi:10.1097/oi9.0000000000000100 · Cited by 6
“daily intake exceeds this value, patients are at increased risk of nephrolithiasis, cardiovascular disease, and stroke.([10]) Nonunion has been shown to significantly worsen functional outcomes, and amplify the cost of care.”
BackgroundAcute Tubular Necrosis Caused by Zoledronic Acid Infusion in a Patient With Osteoporosis
Jani, C., Ueberroth, J. A., Page, S., et al. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001380 · Cited by 5
Won, J., Choi, Y., Lee, B.-C., & Lee, H. (2021) · 대한한의학회지 · doi:10.13048/jkm.21018 · Cited by 4
Atsumi, Y., Rino, Y., Aoyama, T., Okuda, N., KAWAHARA, S., Kazama, K., Numata, M., Tamagawa, H., Oshima, T., Yukawa, N., et al. (2021) · In Vivo · doi:10.21873/invivo.12510 · Cited by 5
Çelebi, Ç. D. (2021) · KADEM Kadın Araştırmaları Dergisi · doi:10.21798/kadem.2021.52 · Cited by 5
Gladkova, E. N., Lesnyak, O. M., Ershova, O. B., et al. (2021) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20212410114 · Cited by 5
Simple Self-Assessment Tool to Predict Osteoporosis in Taiwanese Men
Liu, D.-H., Hsu, C., Wu, P.-C., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.713535 · Cited by 5
“To improve the relevance and effectiveness of these scans, several tools have been developed, such as Osteoporosis Self-Assessment Tool for Asians (OSTA) and the National Osteoporosis Foundation recommendations in 2013 (NOF 2013) (6, 7).”
MethodSharifan, P., Hassanzadeh, E., Mohammadi‐Bajgiran, M., Dabbagh, V. R., Aminifar, E., Ghazizadeh, H., Soflaei, S. S., Darroudi, S., Tanbakouchi, D., Mashhadi, M. R. F., et al. (2022) · PubMed Central · doi:10.22038/abjs.2021.57547.2850 · Cited by 7
Han, S., & Kim, Y.-K. (2021) · Molecules · doi:10.3390/molecules26247579 · Cited by 5
Team Approach: Preoperative Management of Metabolic Conditions in Total Joint Replacement
Liu, C., Brinkmann, E. J., Chou, S. H.-H., Arias, K. T., Cooper, L., Javedan, H., Iorio, R. R., & Chen, A. F. (2021) · JBJS Reviews · doi:10.2106/jbjs.rvw.21.00112 · Cited by 5
Evaluation of Adherence to Guideline-Based Bone Mineral Density Screening in Veterans with HIV
Turin, C. G., Khanjee, N., Breaux, K., Armamento-Villareal, R., Rodriguez-Barradas, M. C., & Clark, E. H. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0095 · Cited by 6
Osteoporosis care gap following fragility fracture in a tertiary teaching hospital
(2021) · Journal of Community Medicine and Public Health Reports · doi:10.38207/jcmphr20210076 · Cited by 5
Development of a Nomogram for Predicting Very Low Bone Mineral Density (T-Scores
Li, Y.-F., Wang, Q.-Y., Xu, L.-L., Yue, C., Hu, L., Ding, N., Yang, Y. Y., Qu, X.-L., & Sheng, Z.-F. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s348947 · Cited by 5
“The WHO classifies BMD diagnosis into normal, low bone mass (osteopenia), osteoporosis, and severe or established osteoporosis.(8) Stratification of patients by level of fracture risk is appropriate, because this may influence initial treatment choice.”
BackgroundIdentification of Vertebral Fractures
Jarraya, M., Hayashi, D., Griffith, J. F., Guermazi, A., & Genant, H. K. (2013) · Medical radiology · doi:10.1007/174_2012_701 · Cited by 5
Factors Associated With Trabecular Bone Score and Bone Mineral Density; A Machine Learning Approach
Moafian, F., Sharifan, P., Darban, R. A., Khorasanchi, Z., Amiri, Z., Roohi, S., Nik, F. M., Bajgiran, M. M., Soflaei, S. S., Darroudi, S., et al. (2022) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2022.06.002 · Cited by 7
van der Keylen, P., Zeschick, N., Schlenz, A. R., & Kühlein, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272985 · Cited by 5
“National Osteoporosis Foundation Clinician’s Guide to Prevention and Treatment of Osteoporosis” (NOF) sets a 10-year risk threshold for any major osteoporosisrelated fracture for pharmacological intervention of� 20% and� 3% for hip fractures [7].”
BackgroundJung, J., Kım, K., Jung, S., Yoon, S., Lee, J. H., Kim, J. S., Shin, H., Bang, S., Sohn, S. K., Suh, C., et al. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.952 · Cited by 7
Hassanabadi, N., Berger, C., Παπαϊωάννου, Α., Cheung, A. M., Rahme, E., Leslie, W. D., Goltzman, D., & Morin, S. N. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06623-4 · Cited by 5
Jiang, X., Yan, N., Zheng, Y., Yang, J., & Zhao, Y. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-06014-0 · Cited by 5
Ranjan, P., Vikram, N. K., Kumari, A., Chopra, S., Choranur, A., Pradeep, Y., Puri, M., Malhotra, A., Ahuja, M., Meeta, et al. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_51_22 · Cited by 6
“Journal of Family Medicine and Primary Care 7561 Volume 11 : Issue 12 : December 2022 constrained setting with limited possibilities of performing a 24-hour recall for assessment of calcium intake, the daily dietary calcium intake can be assessed using a feasible National Osteoporosis Foundation (NOF) tool (as shown i…”
BackgroundMethodYang, P., Li, D., Li, X., Tan, Z., Wang, H., Niu, X., Han, Y., & Lian, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1109427 · Cited by 5
Solgi, S., Zayeri, F., & Abbasi, B. (2023) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_143_22 · Cited by 5
Li, R., Yuan, X., Chen, X., Ou, Y., & Chen, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1358592 · Cited by 8
“…alcohol cessation) and antiresorptive agents as standard therapies for osteoporosis, with bisphosphonates as fi rst-line treatment, were proved to have bene fi cial effects on bone mineral density (BMD) and risk of fragile fractures in postmenopausal women (Cosman et al., 2014; Qaseem et al., 2017).”
BackgroundNon-inferiority margins employed in clinical trials in Japan
Gosho, M. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12268 · Cited by 5
Home monitoring of bone density in the wrist—a parametric EIT computer modeling study
Ron, A., Abboud, S., & Arad, M. (2016) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/2/3/035002 · Cited by 5
Aldasouqi, S. A., Corser, W. D., Abela, G. S., Mora, S., Shahar, K., Krishnan, P., Bhatti, F., Hsu, A., & Gruenebaum, D. D. (2016) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2016.710071 · Cited by 7
Prieto-Peralta, M., Sandoval-Cuéllar, C., & Cobo-Mejía, E. A. (2016) · Fisioterapia · doi:10.1016/j.ft.2016.08.002 · Cited by 11
Elder Abuse Forensics: The Intersection of Law and Science
Heisler, C. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-47504-2_18 · Cited by 7
Bone Density Testing Is the Best Way to Monitor Osteoporosis Treatment
Rothman, M. S., Lewiecki, E. M., & Miller, P. D. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.05.044 · Cited by 5
Self-citationUniversidad Tecnológica de Pereira. Pereira, C., Henao, Y., Universidad de Antioquia. Medellín, C., Botero, P. L., Universidad Tecnológica de Pereira. Pereira, C., F., I. Y. P., Universitat Pompeu Fabra. Barcelona, E., Amariles, P., & Universidad de Antioquia. Medellín, C. (2017) · Salud UIS · doi:10.18273/revsal.v49n3-2017004 · Cited by 5
Putting the Brakes on Breaks: Osteoporosis Screening and Fracture Prevention
Goode, S. C., Beshears, J. L., Goode, R. D., et al. (2017) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151458517743153 · Cited by 5
Oh, S.-H., Kim, D., Lee, Y. E., Kim, D., Lee, Y. K., Lee, J., Bae, S., Choi, Y. Y., Pyo, J., Ahn, J., et al. (2018) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-018-1958-1 · Cited by 5
Du, J. P., Liu, J. J., Fan, Y., et al. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.03.122 · Cited by 5
Nakatoh, S. (2018) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2018.04.009 · Cited by 5
Cao, H., Zhang, L., Chen, H., Zhang, W., Zhang, Q., Liang, X., Guo, Y., & Tang, P. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.7095 · Cited by 4
Jeon, C.-H., Chung, N.-S., Lee, H.-D., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04961-4 · Cited by 5
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.